BACKGROUND: Efavirenz (EFV) association with neurocognitive impairment is debated. Whether switching away from EFV improves neurocognitive performances is still controversial. METHODS: In a randomized open-label controlled trial, patients under effective treatment with tenofovir disoproxil-fumarate (TDF), emtricitabine (FTC) and EFV, who had...
-
2020 (v1)PublicationUploaded on: May 13, 2023
-
2017 (v1)Publication
The study was designed to investigate the median duration of second antiretroviral regimens and factors associated with early discontinuation in HIV patients who switched with an undetectable viral load. We conducted a retrospective analysis of the Italian Cohort Naive Antiretrovirals Foundation Study (ICONA), which collects data throughout the...
Uploaded on: April 14, 2023 -
2006 (v1)Publication
We studied 382 multiexperienced HIV-infected patients followed up for ≥3 months after starting lopinavir/ritonavir (LPV/r) to identify the factors predicting hypertriglyceridemia and high non-HDL cholesterol levels (triglycerides ≥200 mg/dl and/or non-HDL cholesterol ≥190 mg/dl) after 6 and 12 months of LPV/r exposure. The predictors of...
Uploaded on: April 14, 2023 -
2014 (v1)Publication
Objectives: The objective of this study was to assess the 48-week virological efficacy of atazanavir/ritonavir (ATV/r) monotherapy vs. ATV/r along with two nucleoside reverse transcriptase (NRTIs) in HIV-1 treated individuals with HIV-RNA less than 50 copies/ml. Methods: A multicentre, randomized, open-label, noninferiority trial. HIV-1 treated...
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r...
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Background: Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used all-DAA combinations to evaluate their mode of action and...
Uploaded on: April 14, 2023